Healthcare Industry News: HSMN NewsFeed
News Release - January 2, 2018
Abbott Launches Alinity(TM) h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless IntegrationABBOTT PARK, Ill., Jan. 2, 2018 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining the Alinity hq standalone hematology analyzer, which obtained CE Mark earlier this year.
The new Alinity h-series solution integrates the Alinity hq with the Alinity hs slide maker and stainer module into a combined solution. The Alinity h-series solution is 20 percent faster per m2 than other currently available integrated hematology systems with a throughput of 133 complete blood counts (CBCs) per m2.
"Today's hematology laboratories are challenged to perform more tests while reducing errors and operating costs," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "With built-in simplicity designed specifically for hematology testing, the Alinity h-series is smaller, faster, and more automated than current systems, incorporating advanced features that allow health care professionals to spend less time managing the process of producing results and more time helping patients."
Hematology is a medical specialty dedicated to studying the physiology of blood. The Complete Blood Count (CBC), one of the most common hematology tests, is performed to evaluate a patient's overall health and detect a wide range of disorders, like anemia and leukemia. The Alinity hq analyzer automates the performance of the CBC and reports results within a matter of minutes. The Alinity hs module automates blood film preparation and staining, and also has the ability to stain externally prepared blood films.
The integrated Alinity h-series combines extensive insights from customer research with engineering inspiration to address the productivity needs of high-volume laboratories. The system features:
- Enhanced workflow: Integrates workstations, which are currently separated, into a single compact platform. An internal conveyor removes the need for an external track and reduces hands-on time spent by operators to move samples around the laboratory
- Flexibility: Laboratories can scale and integrate the system modules to accommodate their specific needs today and in the future
- Reduced wait time: Continuous access gives the laboratory the ability to add tests and reagents without pausing or stopping the instruments to enable uninterrupted workflow
The integrated Alinity h-series system features an intuitive user experience with iconography, color coding and reporting features shared by all Alinity platforms. Reagent bottles are designed to work like a lock and key to ensure that the right reagents can only be inserted into the right location, preventing costly mistakes and time delays in the lab. The Alinity family of systems also uses a common method for sample loading and reagent management, enabling operators to be trained across platforms more simply and quickly.
To learn more about the Alinity h-series system, visit corelaboratory.abbott/hematology.
Abbott's Alinity family of harmonized solutions is unprecedented in the diagnostics industry, working together to address the challenges of using multiple diagnostics platforms and simplify diagnostic testing. Alinity systems are designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results.
The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics, along with Abbott's AlinIQ—a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics. Alinity is helping labs and hospital systems solve some of their most pressing challenges to deliver better patient care. More information is available at http://www.abbott.com/alinity.
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor
Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon